Education
About Us
Working with TipRanks
Follow Us
MustGrow Biologics (TSE:MGRO)
:MGRO
MGRO Stock Chart & Stats
C$0.59
C$0.01(0.67%)
At close: 4:00 PM EST
C$0.59
C$0.01(0.67%)
Day’s Range― - ―
52-Week RangeC$0.50 - C$1.45
Previous CloseN/A
Volume4.97K
Average Volume (3M)27.52K
Market Cap
C$34.72M
Enterprise ValueC$32.03M
Total Cash (Recent Filing)C$3.28M
Total Debt (Recent Filing)C$583.73K
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Apr 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding58,854,360
10 Day Avg. Volume43,344
30 Day Avg. Volume27,516
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)27.35
Price to Sales (P/S)149.08
P/FCF Ratio-16.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained double-digit TTM revenue growth indicates product traction and expanding market adoption of MustGrow's offerings. Durable top-line expansion supports scaling, channel development, and justifies continued commercial investment, provided the company can translate revenue into improved unit economics over time.
Modest LeverageA conservatively levered balance sheet provides financial flexibility to fund operations, R&D, or commercialization without immediate solvency pressure. Lower debt reduces near-term default risk and gives management room to pursue strategic investments or bridge financing while addressing operating losses.
Favorable Structural MarketMustGrow's bio-based crop protection aligns with long-term industry trends toward sustainable, non-chemical inputs and regulatory scrutiny of fumigants. Structural demand for biologicals can expand the addressable market and create durable adoption tailwinds if the company's technology proves scalable and cost-competitive.
Bears Say
Negative Cash FlowDeeply negative operating and free cash flows signal persistent cash burn and reliance on external funding. This constrains the firm's ability to scale manufacturing, sales, and regulatory activities, increases dilution risk, and elevates execution risk if cash generation doesn't improve within the next several quarters.
Compressed Gross MarginsSharply compressed gross margins undermine the economics of product sales and limit internal funding for SG&A and R&D. Even with revenue growth, margin pressure reduces the likelihood of sustainable profitability and forces difficult trade-offs between price competitiveness and long-term margin restoration.
Volatile Negative EarningsPersistent, volatile net losses point to an unstable operating model and execution risk. Unpredictable earnings make strategic planning and forecasting difficult, elevate the cost of capital, and may impede the company's ability to secure patient financing while it seeks to stabilize margins and cash generation.
MustGrow Biologics News
MGRO FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was C$0.50 and its highest was C$1.45 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is C$34.72M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Apr 23, 2026 which is in 60 days.
How were MustGrow Biologics’s earnings last quarter?
MustGrow Biologics released its earnings results on Nov 25, 2025. The company reported -C$0.04 earnings per share for the quarter, the consensus estimate of -C$0.04 by C$0.
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 58,854,360 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
MustGrow Biologics reported an EPS of -C$0.04 in its last earnings report, expectations of -C$0.04. Following the earnings report the stock price went up 6.78%.
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in TSE:MGRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp., an agricultural biotech company, focuses om development and commercialization of natural biopesticide, biofumigants, and bioherbicides derived from mustard seed. It provides preplant soil biofumigation, a technology to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and other crops. The company is also developing bioherbicide to treat unwanted plant growth for use in organic agriculture, home, and garden markets, as well as agriculture markets; and postharvest food preservation, an application in sprout, disease, and pathogen treatment for storage and food preservation markets. In addition, it focuses on providing CannaPM, an active ingredient to treat fungal soil diseases, as well as foliar diseases. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.
MGRO Earnings Call
Q3 2025
0:00 / 0:00
MGRO Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―
Options Prices
Currently, No data available
---